My Biggest Mistake: Sticking With Gilead Too Long (Bret Jensen)

| About: Gilead Sciences, (GILD)

Summary

Bret believes that he stuck with Gilead for too long.

Company is still ridiculously undervalued based on cash flow.

Hepatitis C market share is holding steady and HIV franchise is strong.

Bret shares expectation for sentiment to change and what he thinks the floor is for stock price.

*The following is a full excerpt of an interview with Bret Jensen from the June DIY Investing Summit.

Bret Jensen is one of nine Seeking Alpha Contributors participating in the 2017 DIY Investing Summit. In the summit, one of the questions I asked Bret was what he thinks one of his biggest mistakes has been so far this year (and what he's learned from it). Below is his response.

Bret's biggest mistake so far this year...

  • Bret believes that he stuck with Gilead (NASDAQ:GILD) for too long
  • Even so, he things the company is still ridiculously undervalued based on cash flow
  • Hepatitis C market share is holding steady and the HIV franchise is strong
  • Just a matter of "when" sentiment will change
  • Hard to see sentiment getting worse from here
  • Bret shares why and when he expects sentiment to change and what he thinks the floor to be for GILD stock (Mid-$60s)
  • More...

Interview excerpt (interview starts at 1:10):

This is just a small excerpt of what's covered in the interview.

The interview is full of detailed tips on Bret's core investment strategies, top advice for DIY investors and specific ways he's positioning for second half of 2017.

Enjoy the full interview with Bret and other top investors on Seeking Alpha. Registration for the summit is now open and free for a limited time.

Full list of summit contributors:

  • Bret Jensen
  • Brad Thomas
  • J Mintzmyer
  • Eric Parnell
  • Ian Bezek
  • Lawrence Fuller
  • Double Dividend Stocks
  • Mark Hibben
  • William Koldus

For readers who prefer to read content as opposed to watch and listen, detailed summary sheets have been created for every interview as an optional add-on.

Join Bret at the DIY Investor Summit (free for a limited time) where he shares detailed tips on his core investment strategies, top advice for DIY investors and specific ways he's positioning for second half of 2017.

Companies mentioned in Bret's interview: Gilead Sciences, Supernus (NASDAQ:SUPN), Portola (NASDAQ:PTLA), Celgene (NASDAQ:CELG), Allergan (NYSE:AGN), Omeros (NASDAQ:OMER), Synergy (NASDAQ:SGYP), Flexion (NASDAQ:FLXN), Dynavax (NASDAQ:DVAX)

Additional Disclosure: This article is for information purposes only. There are risks involved with investing including loss of principal. Brian and Investor in the Family make no explicit or implicit guarantee with respect to performance or the outcome of any investment or projections made. There is no guarantee that the goals of the strategies discussed by Brian and Investor in the Family will be met.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

About this article:

Expand
Author payment: $35 + $0.01/page view. Authors of PRO articles receive a minimum guaranteed payment of $150-500.
Tagged: , , , Biotechnology
Want to share your opinion on this article? Add a comment.
Disagree with this article? .
To report a factual error in this article, click here